# Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Source: https://onco.cc/trials/nct02864992/  
OnCo record `nct02864992` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tepotinib in non-small-cell lung cancer and small-cell lung cancer, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.

## Summary

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) is a phase 2 interventional study registered as NCT02864992 by EMD Serono Research & Development Institute, Inc., with 337 participants enrolled, started 2016-09-13 and due to reach its primary completion in 2022-05-16. Interventions recorded: Tepotinib. Conditions listed: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02864992
- Phase: 2
- Setting: A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Enrolled: 337

## Sources

- ClinicalTrials.gov NCT02864992: https://clinicaltrials.gov/study/NCT02864992

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Tepotinib](https://onco.cc/drugs/tepotinib/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)

---
JSON: https://onco.cc/api/v1/entities/nct02864992.json